Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Etrasimod for Induction and Maintenance Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis

NCT04176588 is registered in ClinicalTrials.gov with Everstar Therapeutics Limited as lead sponsor.

NCT NCT04176588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04176588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Etrasimod for Induction and Maintenance Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
Everstar Therapeutics Limited
Phase
Phase 3
Overall status
Unknown status
Start date
September 10, 2019
Completion date
October 31, 2024
Enrollment
341 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

moderately to severely active ulcerative colitis